PTC Therapeutics (PTCT) News Today $43.84 +0.76 (+1.76%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Assenagon Asset Management S.A. Decreases Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Assenagon Asset Management S.A. trimmed its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 10.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 439,670 shares of the biopharmaceutical compaJanuary 18 at 3:40 AM | marketbeat.comCantor Fitzgerald Has Lowered Expectations for PTC Therapeutics (NASDAQ:PTCT) Stock PriceJanuary 18 at 3:37 AM | americanbankingnews.comCantor Fitzgerald Has Positive View of PTCT FY2024 EarningsPTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Stock analysts at Cantor Fitzgerald upped their FY2024 earnings per share (EPS) estimates for PTC Therapeutics in a report issued on Wednesday, January 15th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company wilJanuary 17 at 6:40 AM | marketbeat.comWilliam Blair Has Optimistic Outlook of PTCT FY2024 EarningsPTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - William Blair increased their FY2024 earnings estimates for shares of PTC Therapeutics in a report released on Monday, January 13th. William Blair analyst S. Corwin now expects that the biopharmaceutical company will post earnings of ($5.33) peJanuary 16 at 6:34 AM | marketbeat.comPTC Therapeutics price target lowered at Cantor Fitzgerald, a top pick in 2025January 15 at 3:03 PM | markets.businessinsider.comPTC Therapeutics (NASDAQ:PTCT) Price Target Lowered to $76.00 at Cantor FitzgeraldCantor Fitzgerald lowered their target price on PTC Therapeutics from $80.00 to $76.00 and set an "overweight" rating on the stock in a report on Wednesday.January 15 at 7:59 AM | marketbeat.comPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 13, 2025 | prnewswire.comPTC Therapeutics sees FY25 revenue $600M-$800MJanuary 13, 2025 | markets.businessinsider.comPTC Therapeutics sees FY25 revenue $600M-$800M, consensus $963.31MJanuary 13, 2025 | markets.businessinsider.comPTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 13, 2025 | prnewswire.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Sells $69,959.62 in StockJanuary 13, 2025 | americanbankingnews.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells $72,498.66 in StockJanuary 13, 2025 | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Insider Sells $57,355.10 in StockJanuary 13, 2025 | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Sells $36,725.40 in StockJanuary 11, 2025 | insidertrades.comPTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Lee Scott Golden Sells 810 SharesPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) EVP Lee Scott Golden sold 810 shares of the business's stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $45.34, for a total transaction of $36,725.40. Following the completion of the transaction, the executive vice president now directly owns 79,849 shares of the company's stock, valued at approximately $3,620,353.66. This represents a 1.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.January 10, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 1,265 SharesPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) insider Neil Gregory Almstead sold 1,265 shares of PTC Therapeutics stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $45.34, for a total transaction of $57,355.10. Following the sale, the insider now directly owns 104,783 shares in the company, valued at approximately $4,750,861.22. This trade represents a 1.19 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.January 10, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Christine Marie Utter Sells 1,291 SharesPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) CAO Christine Marie Utter sold 1,291 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $45.34, for a total transaction of $58,533.94. Following the sale, the chief accounting officer now directly owns 65,983 shares of the company's stock, valued at approximately $2,991,669.22. This trade represents a 1.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.January 10, 2025 | marketbeat.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Sells 1,543 Shares of StockPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) VP Mark Elliott Boulding sold 1,543 shares of the business's stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $45.34, for a total value of $69,959.62. Following the sale, the vice president now directly owns 108,846 shares of the company's stock, valued at $4,935,077.64. This represents a 1.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.January 10, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells $72,498.66 in StockPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) CEO Eric Pauwels sold 1,599 shares of the stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $45.34, for a total value of $72,498.66. Following the transaction, the chief executive officer now owns 88,941 shares of the company's stock, valued at $4,032,584.94. This represents a 1.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.January 10, 2025 | marketbeat.comJPMorgan Chase & Co. Cuts Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)JPMorgan Chase & Co. decreased its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 17.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 562,781 shares of the biopharmaceutical company's stock after selling 118,152 shareJanuary 9, 2025 | marketbeat.comPTC Therapeutics price target lowered to $58 from $63 at RBC CapitalJanuary 8, 2025 | markets.businessinsider.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells 8,279 Shares of StockJanuary 4, 2025 | insidertrades.comPTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells $373,879.64 in StockPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) CEO Matthew B. Klein sold 8,279 shares of the stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $45.16, for a total value of $373,879.64. Following the completion of the transaction, the chief executive officer now directly owns 217,528 shares of the company's stock, valued at $9,823,564.48. This trade represents a 3.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.January 3, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of "Hold" by AnalystsPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) has been assigned an average rating of "Hold" from the fifteen analysts that are covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, three have assigned a hold rating, eight have assignedDecember 29, 2024 | marketbeat.comPTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 23, 2024 | prnewswire.comGeode Capital Management LLC Buys 10,886 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Geode Capital Management LLC boosted its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 0.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,798,666 shares of the biopharmaceutDecember 22, 2024 | marketbeat.comPTC Therapeutics submits NDA for vatiquinone in Friedreich ataxiaDecember 19, 2024 | markets.businessinsider.comPTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich AtaxiaDecember 19, 2024 | prnewswire.comPTC Therapeutics (NASDAQ:PTCT) Rating Lowered to "Hold" at StockNews.comStockNews.com downgraded PTC Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday.December 18, 2024 | marketbeat.comPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 17, 2024 | prnewswire.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Y Intercept Hong Kong LtdY Intercept Hong Kong Ltd trimmed its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 57.0% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,829 shares of the biopharmaceutical company's stockDecember 16, 2024 | marketbeat.comState Street Corp Increases Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)State Street Corp raised its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 5.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,899,040 shares of the biopharmaceutical company'sDecember 16, 2024 | marketbeat.comPTC Therapeutics (PTCT) Receives a Buy from RBC CapitalDecember 13, 2024 | markets.businessinsider.comPTC Therapeutics (NASDAQ:PTCT) Upgraded to "Overweight" at Morgan StanleyMorgan Stanley upgraded PTC Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their price target for the stock from $45.00 to $67.00 in a research note on Friday.December 13, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 12.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 133,977 shaDecember 12, 2024 | marketbeat.comCantor Fitzgerald says ‘aggressively’ buy uniQure, PTC TherapeuticsDecember 11, 2024 | markets.businessinsider.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by Two Sigma Advisers LPTwo Sigma Advisers LP raised its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 10.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 429,842 shares of the biopharmaceutical company's stock after purchasing an additional 40,300 sharesDecember 9, 2024 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Fmr LLCFmr LLC lowered its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 4.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,057,182 shares of the biopharmaceutical company's stock aDecember 9, 2024 | marketbeat.comWellington Management Group LLP Cuts Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT)Wellington Management Group LLP reduced its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 3.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,892,799 shares of the biopharmaDecember 8, 2024 | marketbeat.comBNP Paribas Financial Markets Cuts Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)BNP Paribas Financial Markets cut its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 42.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 72,946 shares of the bioDecember 7, 2024 | marketbeat.comPTC Therapeutics: Hold Rating Amid Strategic Collaboration with Novartis and Clinical UncertaintiesDecember 6, 2024 | markets.businessinsider.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Janus Henderson Group PLCJanus Henderson Group PLC lowered its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 37.3% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,870,217 shares of the biopharmaceutical company's stock after selling 1,111,342 shares duDecember 6, 2024 | marketbeat.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Sells 17,800 Shares of StockDecember 5, 2024 | insidertrades.comPTC Therapeutics price target raised to $32 from $26 at CitiDecember 5, 2024 | markets.businessinsider.comCharles Schwab Investment Management Inc. Acquires 47,902 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Charles Schwab Investment Management Inc. boosted its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 7.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 706,730 shares of the biopharmaceuticalDecember 5, 2024 | marketbeat.comParkman Healthcare Partners LLC Takes $7.23 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Parkman Healthcare Partners LLC bought a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 195,000 shares of the biopharmaceutical company's stock, valued at approximaDecember 4, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Lowers Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Jacobs Levy Equity Management Inc. reduced its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 13.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,486,297 shares of the biopharmaceutDecember 4, 2024 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Consensus Recommendation of "Hold" from AnalystsPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) has been assigned a consensus rating of "Hold" from the fifteen research firms that are covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, four have given a hold rating, seven have gDecember 4, 2024 | marketbeat.comPTC Therapeutics price target raised to $41 from $31 at BofADecember 3, 2024 | msn.comBarclays Keeps Their Hold Rating on PTC Therapeutics (PTCT)December 3, 2024 | markets.businessinsider.com Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address PTCT Media Mentions By Week PTCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTCT News Sentiment▼0.310.64▲Average Medical News Sentiment PTCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTCT Articles This Week▼206▲PTCT Articles Average Week Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ITCI News SMMT News MRNA News RDY News CTLT News SRPT News QGEN News PCVX News ASND News ROIV News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTCT) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
